Recursion Pharmaceuticals Company Insiders

Recursion Pharmaceuticals Management Team Effectiveness

The company has return on total asset (ROA) of (0.364) % which means that it has lost $0.364 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.7849) %, meaning that it created substantial loss on money invested by shareholders. Recursion Pharmaceuticals' management efficiency ratios could be used to measure how well Recursion Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.55 in 2025. Return On Capital Employed is likely to drop to -0.75 in 2025. At this time, Recursion Pharmaceuticals' Net Tangible Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 260.3 M in 2025, whereas Total Assets are likely to drop slightly above 520.4 M in 2025. Common Stock Shares Outstanding is likely to drop to about 194.8 M in 2025. Net Loss is likely to drop to about (226.3 M) in 2025

Recursion Pharmaceuticals Workforce Comparison

Recursion Pharmaceuticals Insider Trading History

Recursion Pharmaceuticals Notable Stakeholders

The success or failure of an entity such as Recursion Pharmaceuticals often depends on how effective the management is. Recursion Pharmaceuticals management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Recursion management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Recursion management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.

Please note, the imprecision that can be found in Recursion Pharmaceuticals' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Recursion Pharmaceuticals. Check Recursion Pharmaceuticals' Beneish M Score to see the likelihood of Recursion Pharmaceuticals' management manipulating its earnings.

When running Recursion Pharmaceuticals' price analysis, check to measure Recursion Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Recursion Pharmaceuticals is operating at the current time. Most of Recursion Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Recursion Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Recursion Pharmaceuticals' price. Additionally, you may evaluate how the addition of Recursion Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.